Saxenda
Coverage of Saxenda in the Nexus archive.
- Which GLP-1 works best? New meta-study puts them head-to-head
A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated their effectiveness in a head-to-head analysis.
- Which GLP-1 works best? New meta-study puts them head-to-head
A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza).
- Which GLP-1 works best? New meta-study puts them head-to-head
A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza) to determine their effectiveness.
- People who lost the most weight on Ozempic saw huge health benefits
People who lost significant weight on Ozempic saw lower risks of obesity-related health problems like sleep apnea and kidney disease, while those who gained weight faced higher risks, especially for heart failure. Significant weight loss was associated with sharply lower health risks. Many patients discontinued medications within a year.
- STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
France's medicines regulator fined Novo Nordisk approximately $2 million and Eli Lilly roughly $127,000 for misleading advertisements for their weight loss medications. The penalties reflect increasing concern among regulators that weight loss medicines may be misused. The regulator is closely scrutinizing promotions run by pharmaceutical companies.